In 2008, SBP was awarded a $97.9 million grant by NIH to establish a high-throughput screening center. In 2010, the Institute adopted the name Sanford-Burnham Medical Research Institute following a $50 million pledge of support from Sanford. An anonymous gift of $275 million was made in 2014. In 2015, the Institute changed its name again to Sanford Burnham Prebys Medical Discovery Institute following a $100 million gift from philanthropist Conrad Prebys. SBP was founded with its primary focus on cancer research. SBP ranks consistently among the world's top 25 organizations for its research impact, according to Thomson Scientific data. It also ranks among the top 3% of research institutes in the United States in National Institutes of Health grant funding. Research staff in SBP’s laboratories numbers over 520 including postdoctoral researchers; an additional 30 graduate students and 164 administrative and support personnel to bring the total number of employees to over 700. The institute is home to four research centers:   The Sanford Burnham Prebys Medical Discovery Institute has 7 research programs including:  SBP is one of five institutes that have joined together to carry out stem cell research in a partnership named for donor T. Denny Sanford. The Sanford Consortium for Regenerative Medicine opened a $126 million research facility in 2011 and is a joint venture of SBP, the Salk Institute, Scripps Research, UC San Diego, and the La Jolla Institute for Immunology. Insights into the complex system of networks and mechanisms that tumors use to survive and proliferate. Findings build dialogue with clinicians and physician scientists across the country and in neighboring institutions to ensure the translational and human relevance of the research. Understanding how cells discriminate between functional and nonfunctional proteins. Discoveries about the damaging impact of oxidative stress on protein structure and function in the neurodegenerative diseases of Alzheimer’s and Parkinson’s, metabolic diseases of diabetes and liver failure, and inflammatory disease and cancer. Findings are translated into new therapies that improve protein folding and preserve cell function in diseases that have global health impact. Using model organisms—mice, fish, flies, worms and human stem cells to (1) unravel gene functions linked to mutations and epigenetic factors; (2) explore the development and regenerative capacity of the brain, heart, muscles, pancreas, limbs, liver and other organs; and (3) probe the biology of aging and organ/tissue maintenance to maintain a well-functioning organism. Insights provide the tools needed to uncover novel therapeutic targets for heart disease, neurodegeneration, muscle disorders, diabetes, cancer and other debilitating diseases.